Sign up for the QMED & MD+DI Daily newsletter.
One Year After Guidant Deal, Boston Scientific Stronger, Some Say
The Boston Globe has a piece analyzing the Boston Scientific-Guidant deal one year after it was consummated, and it comes to some unexpected conclusions. A number of investors and analysts believe the company is stronger today because of the deal, because it would have been significantly weakened without it. The market for its core business before the deal, stents, has declined over the past year thanks to studies that have questioned their safety and efficacy.
April 23, 2007
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
Whereas the market for implantable heart devices has started to rebound over the past year. So, while the much-maligned deal has not achieved what Boston Scientific management hoped for, it has made the firm much healthier than it would have been had it continued to rely on stents so heavily. CEO Jim Tobin is quoted as saying Boston Scientific would be in "deep doodie" without Guidant. If he's willing to go on the record with that kind of comment, you know he means it.
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
.png?width=300&auto=webp&quality=80&disable=upscale)